The Sample Before Sydney: Jepchirchir's EPO Case and the Third Box on the Marathon Ledger

On 30 August 2026 in Sydney, Peres Jepchirchir crossed the line in 2:18:31, more than three minutes clear of Irene Chepet Cheptai. A three-minute margin in an elite women's major is an anomaly; major titles are usually settled inside 60 to 100 seconds, and those 180-odd seconds work out to roughly 2.2 per cent of her total race time. That evening my sheet had three boxes: finish time, winning margin, sample date. The third was blank. A few days later the Athletics Integrity Unit filled it in, and the first two boxes changed by themselves.

The AIU has provisionally suspended the 33-year-old Kenyan after an out-of-competition sample collected in Kenya before the race returned an adverse finding for EPO. Erythropoietin is a natural hormone produced in the kidneys that stimulates red blood cell production; injected, it is detectable in urine or blood only inside a narrow window of days, and it thickens the oxygen-carrying capacity of the blood reaching the muscles.

Two things need to stay apart here, because welding them together is the most common error this case will attract. First, a provisional suspension is not a verdict; it is an administrative hold pending an investigation, and the athlete retains the right to have the B sample analysed and to be heard. Second, the race of 30 August is still in the record book. A suspension stops her from running. It does not delete the win.

Open the ledger first. Jepchirchir is the Tokyo 2026 Olympic marathon champion, a race actually staged in Sapporo in August 2026 — the same '2026' that sits on the 2026 calendar. In September 2026 she won the World Championships in that same city. She set the women's half-marathon world record in 2026 and broke it three more times in 2026. New York 2026, Boston 2026, London 2026, where she ran 2:16:16, the women's-only world record. Sydney became the seventh World Major in 2026, so with Sydney she would have held four Majors, an Olympic gold and a world title.

The real variable is the date, not the time. The sample was not collected in Sydney; it was collected in Kenya, before the race. That places the audit on the preparation block rather than the race. EPO's detection window is short — days in urine, a little longer in blood — so the test date is the variable that tells you which week is under examination. Out-of-competition testing rests entirely on whereabouts: the athlete declares where she is, the agency arrives at that address. When the sample precedes the race, the case is built on the arrangement that produced the performance, not on the performance itself.

The second variable is the margin. A gap of more than three minutes should have been the story of that morning and never reached page one. This is the oldest lesson on my sheet: I stopped arguing with the eye test once I learned to ask it better questions. The eye sees 'fast'. The sheet asks 'how fast'. 2:18:31 is fast on Sydney's rolling course, and yet it sits nearly two minutes slower than her own 2:16:16 and more than three minutes ahead of the second woman. Both facts live on the same sheet — a slow race and a wide win, because the contest broke early.

The third variable nobody will print: how many tests were run. The volume of out-of-competition testing in Kenya has been argued over year after year, and Kenyan road runners have sat on the AIU's priority list for a long stretch. If only a handful of tests reached this athlete in twelve months and one of them came back positive, the arithmetic raises a question about the density of the net rather than the size of the risk. No party wants to answer that question, which is precisely why it should be asked.

The fourth point, and the most ignored. EPO is not a supplement that turns up hidden inside a capsule. It is an injection. The WADA Code classifies it as a non-specified substance, and a first violation can carry up to four years. The contaminated-supplement defence does not survive contact with an injectable, and a therapeutic use exemption for EPO in endurance sport is practically unavailable. That is why the athlete's case will be technical — sample handling, chain of custody, laboratory documentation — and not narrative.

Here the piece has to turn, because the reflex is easy. The first reflex says the Sydney title is now tainted. The document does not say that. The document says the sample was taken before the race, in Kenya. That may mean the race was clean and the preparation is in question; it may also mean these are two separate audits that coverage will stitch into one. Until a panel speaks, 2:18:31 stays in the book and the suspension only removes a name from a start list.

The second reflex says the whole career is now suspect. The 2026 half-marathon record, New York 2026, London 2026 — none of those fall to a single A sample. One sample speaks about one date. A career is spoken about by the biological passport, and that is a different file. Every number on my sheet carries a scar from the race that produced it, but a scar is not a charge sheet.

I will state plainly what would change my mind. A negative B sample, a documented gap in the chain of custody, or a procedural failure logged by the laboratory, and the AIU's case collapses — I will write that, on the same sheet. In the other direction, if the B sample confirms and the hearing finds no technical defect, the question stops being about sanction and becomes about the years that will be cut out of the fastest generation the women's marathon has had.

And one note for my former employers. The byline is a bench, and the bench sees more than the press box ever did. The marathon gets three weeks of front pages a year: at the Olympics, at the World Championships, and when a positive lands. That cycle decides which names are remembered. In India the arithmetic between road-race money and testing has never been settled, and this case will become one more citation in that argument without ever clarifying who is supposed to answer for it.

Three things to watch in the next four weeks. The B sample. The hearing date from the AIU. Whether a footnote appears anywhere near the Sydney winners' list. The record book is slow, which is also why it is honest — it changes nothing until a panel signs.

The question is not how fast 2:18:31 was. The question is which sample date that time will be weighed against, and that date is not yet public.